However, Nijhof and coworkers have demonstrated that ATRA treatment is also able to reduce CD55 and CD59 expression on anti-CD38-resistant MM cells, thus supporting the use of a combined therapy to improve complement-mediated cytotoxicity (CDC) against malignant cells (21). This evidence concerns the gene CD38 and Miyoshi myopathy.